USFDA issues warning letter to Divis Labs’ Vishakhapatnam facility

24 Apr 2017 Evaluate

United States Food and Drug Administration (USFDA) has issued a warning letter to Divis Laboratories’ Unit-II at Vishakhapatnam facility. The company along with external consultants and subject matter experts is working to address the concerns of USFDA and is making all efforts to fully meet the compliance requirements.

The company has responded to USFDA inspection observations with an appropriate remediation process to overcome the deficiencies observed.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Divis Lab Share Price

6394.65 -30.85 (-0.48%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×